Media 23 Jan 2025 Stockhead | Orthocell soars 14% after crushing early sales growth for Remplir Orthocell's plans to broaden its commercial footprint in existing and new markets drove the company's share price up 13.8% this… Orthocell
Company News 22 Jan 2025 Orthocell Accelerates Global Expansion: Five New Country Regulatory Submissions Planned in 2025 On the back of outstanding early sales traction for Remplirâ„¢ in Australia, New Zealand and Singapore, Orthocell has announced that… Orthocell
Company News 20 Jan 2025 Orthocell receives $3.18m R&D tax incentive refund Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year. Orthocell
Media 08 Jan 2025 Stockhead Special Report | Orthocell achieves third consecutive quarter of record revenue Orthocell has been featured in a special report on Stockhead highlighting Orthocell's consistent growth in sales of our regenerative medicine… Orthocell
Company News 08 Jan 2025 OCC Quarterly Report | Quarter ended 31 December 2024 Orthocell has recorded a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter. Orthocell
Media 03 Jan 2025 Podcast | Talk Ya Book Orthocell Chairman John Van Der Wielen recently spoke with podcast host Chris Judd on Talk Ya Book to discuss the… Orthocell
Media 03 Jan 2025 The West Australian | Orthocell cracks a new record high Orthocell has been featured in The West Australian in an article by Sean Smith titled “Orthocell cracks a new record… Orthocell
